Filing Flows › AIM ImmunoTech (AIM) › Q2 2025
AIM ImmunoTech (AIM) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 14, 2025
AIM ImmunoTech (AIM) reported revenue of $25K for the second quarter 2025 (Q2 2025), -50% from a year earlier and +56% from the quarter before.
AIM ImmunoTech, Q2 2025: revenue $25K (-50% year over year), net loss $2.8M, operating cash flow −$1.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $25K | +56% | -50% |
| Operating profit | −$2.6M | — | — |
| Net earnings | −$2.8M | — | — |
| Operating cash flow | −$1.5M | — | — |
What changed
Revenue was $25K in Q2 2025, down 50% year over year and up 56% from the previous quarter.
Operating costs exceeded revenue by $2.6M, an operating margin of -10584.0%. Total costs fell 29% while revenue fell 50%. The quarter ended with a net loss of $2.8M, narrower than the previous quarter's $3.7M loss.
Operating cash flow was −$1.5M. Non-cash charges added back $55K of depreciation and amortization. Working capital and other items added $1.2M.
Questions
What was AIM ImmunoTech's revenue in the second quarter 2025?
AIM ImmunoTech (AIM) reported revenue of $25K for the second quarter 2025 (Q2 2025), -50% from a year earlier and +56% from the quarter before.
Source: AIM ImmunoTech 10-Q on SEC EDGAR.